ASN supports quality pre-transplant, transplant, and post-transplant care. The expansion of immunosuppressive drug coverage for kidney transplant patients, a longstanding ASN policy priority, was enacted into law after decades of advocacy. 

In December 2020, the US Senate passed the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act as part of a broad year-end legislative package, extending Medicare coverage of life saving immunosuppressive medications for the life of the kidney transplant. The law is expected to save Medicare $400,000,000 over 10 years by averting the return of transplant patients to dialysis.

The following articles relate to initiatives and activities that align with ASN’s efforts to identify, prioritize, and advocate for policies that promote the highest quality patient care, increased funding for research, and a commitment to medical education funding for kidney diseases on the federal legislative, regulatory, and profession-sanctioned levels.